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Abstract  
A UPLC-MS/MS assay, employing a reversed-phase separation, has been applied to the 
analysis of a number of common amino acids and biogenic amines in rat urine.  Analytes 
were derivatised, using 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AccQTag 
Ultra
TM)
. Derivatisation with this reagent, by increasing the hydrophobicity of the analytes, 
enables better retention by improving reversed-phase chromatographic properties and also 
improves ionisation efficiency to enhance MS-detection. The method allows for the 
determination of 38 amino compounds in 7.5 minutes, including baseline resolution of critical 
isomers. The assay has been validated for the absolute quantification of 29 amino compounds 

















metabolite phenotyping.  Acceptable linearity (R
2 
> 0.995) and intra- and inter-day accuracy 
(< 20.7 %) and precision (< 20.1 %) for these analytes was achieved.  The limits of detection 
ranged from 1.2-12 fmol on column with 20 µL of sample.  The remaining nine amines 
examined were not accurately quantified by this method but can be monitored for 
relative/fold change in biological samples.  The use of the method is exemplified by the 
monitoring of changes in healthy male Sprague-Dawley rat urinary amino acid concentrations 

























The metabolic phenotyping of the endogenous metabolites, present in biological fluids or 
tissue samples, undertaken with the aim of discovering novel biomarkers, or patterns of 
biomarkers, can be used to characterise the biochemical status of the system under 
investigation [1]. However, the methods used to obtain these “metabotypes” are often 
qualitative, or semi-quantitative and, once discovered, these putative biomarkers require 
confirmation and quantification using a “targeted” method.  Unlike untargeted global 
profiling methods, targeted assays focused on specific classes of compounds (or metabolites 
representative of key pathways) permit the optimization of sample preparation, 
chromatographic separation and mass spectrometry (MS) conditions for the analytes of 
interest, offering the most sensitive and specific analysis [2]. One class of compounds that are 
frequently found to be important potential biomarkers are amino acids and other biogenic 
amines which play key roles in e.g., in inherited metabolic diseases [3], neurological 
disorders [4], cancers [5, 6], diabetes [7, 8] and obesity [9].  Amino compounds including 
amino acids, are inherently challenging to analyse due to their lack of volatility, requiring 
derivatisation for gas chromatography (GC), whilst their highly polar and, in the case of 
amino acids, amphoteric nature can make analysis by liquid chromatography (LC) 
problematic.  Nevertheless, since the introduction of paper chromatography-based methods 
for their analysis in clinical analysis (see e.g., [10]) a large number of methods for the 
analysis of this class of compounds have been described including those based on separation 
and detection using e.g., LC-UV [11], LC-fluorescence [12], CE[13], CE-MS/MS[14], GC-
MS [15] and both reversed-phase and HILIC LC-MS/MS [16-18].  We have recently 
described a UPLC-MS-based method for the sensitive and specific determination of amino 
compounds in human plasma and serum based on the derivatization of primary and secondary 



















) [19]. Although originally developed as a fluorescence label this reagent 
has also found application in MS detection [20-25] for the analysis of proteinogenic amino 
acids and enables the detection of any primary or secondary amine via a common fragment 
ion (m/z 171) resulting from the loss of the aminoquinoline moiety.  The derivatives 
produced via the use of 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate are, unlike the 
free amino compounds, well retained in reversed-phase chromatographic systems providing 
the basis for a sensitive and selective method for quantification. Here we describe 
development and validation of the methods for the quantitative analysis of 29 physiological 
amino compounds, and the monitoring of a further 9, present in rat urine with application to 
control rat urine samples obtained over a 7-day period.  
2 Material and Methods 
2.1 Materials 
Amino acid standards, including physiological acids, neutrals and bases, were purchased 
from Sigma Aldrich (Gillingham, UK).  The stable isotopically labelled (SIL) amino acids 
used as internal standards (IS) were DL-Alanine-d3, DL-aspartic acid-d3, DL-glutamic acid-
d3, L-glutamine-d5, L-isoleucine-d10, DL-leucine-d10, DL-phenylalanine-d5, DL-proline-d7, 
DL-serine-d3, L-threonine-
13
C4, L-tryptophan-d5, DL-tyrosine-d7 and DL-valine-d8 were 
purchased from Cambridge Isotope Laboratories (MA, USA).  DL-Histidine-d3, DL-lysine-d4 
and DL-methionine-d3 were purchased from QMX Laboratories (Essex, UK).  Optima grade 
water was obtained from Fisher Scientific (Leicester, UK), LC-MS grade acetonitrile, 
methanol, isopropanol and formic acid were purchased from Sigma Aldrich (Gillingham, 
UK).  The AccQTag Ultra derivatisation reagent
TM
 was obtained from Waters Corporation 

















2.2 Preparation of Stock Solutions 
Stock solutions of amino compound were prepared at 1 mg/mL in water, except for cystine 
and tyrosine which were dissolved in 0.1M HCl.  The analytes were derivatized as described 
in [19] and the optimisation of MS parameters for the aminoquinolone derivatives (e.g., 
capillary voltage, cone voltage and collision energy) performed by infusing each analyte (200 
ng/mL) at 10 µL/min combined with a LC flow of 50:50 H2O/CH3CN at 0.2 mL/min.   
Similarly, calibration standards and quality control (QC) samples were prepared from a 
standard mixture of neutral, basic and acidic physiological amino acids (Sigma Aldrich, 
Gillingham, UK) with the addition of asparagine and glutamine.  For each validation 
exercise, a working stock solution (400 µM) was made of all the compounds in duplicate 
dissolved in 50:50 H2O/CH3OH (v/v) to give two solutions (A and B).  Stock solution A was 
used for preparing the calibration standards, over the range 0.2-200 µM, and stock solution B 
for the validation and QC samples with both diluted with 50:50 H2O/CH3OH (v/v). In the 
absence of analyte-free matrix QC samples were prepared in water. The QC samples were 
prepared so as to cover the lower limit of quantification, low, medium, high and upper limit 
of quantification for each amino acid for the determination of intra- and inter-assay 
performance.  Stock solutions of each SIL amino acid at 1 mg/mL were prepared in Optima 
grade water.  Individual stock solutions were combined to provide a working stock solution at 
a concentration of 30 µg/mL in 50:50 H2O/CH3OH (v/v) that was further diluted to a final 
working concentration of 2 µg/mL.  
2.3 Sample Preparation  
2.3.1 Urine samples  
Male Sprague-Dawley rats (8 weeks of age) were housed in metabolic cages for 7 days as 

















Urine samples (24h) were collected daily for 7 days from 10 healthy control male rats. All 
samples were stored at -40 °C until analysis, at which point they were thawed at 4 °C and 20 
µL aliquots were transferred to Eppendorf tubes. In order to precipitate protein from both rat 
urine, 60 µL of cold methanol (-20 °C) containing 0.1 % formic acid (v/v) was added to each 
sample.  The samples were then vortex mixed and left at -20 °C for 20 min before 
centrifugation at 13 000 g for 10 min, after which 5 µL of the supernatant was combined with 





 (6-aminoquinolyl-n-hydroxysuccinimidyl carbamate) derivatisation 
reagent was prepared by the addition of 1 mL acetonitrile to the AccQTag Ultra
TM
 powder, 
vortex mixing for several seconds and heating at 55 °C until dissolved.  For derivatisation 10 
µL of solutions of standards or samples were aliquoted into glass HPLC vials, or 96-well 
plates, together with 70 µL borate buffer (pH 8.6) and vortex mixed followed by 20 µL of 
AccQTag Ultra
TM
 reagent solution. The samples were vortex mixed for several seconds and 
the vial placed on a heating block at 55°C for 10 minutes followed by dilution 1 in 100 (v/v) 
with Optima grade water prior to LC-MS/MS. 
2.4 UPLC-MS Conditions 
Liquid chromatographic analysis was performed using 2 µL of sample injected onto a HSS 
T3 2.1 x 150 mm, 1.8 µm column (Waters Corp., Milford, MA, USA) on an Acquity UPLC 
system (Waters Corp., Milford, MA, USA) hyphenated to a Xevo TQ-S tandem quadrupole 
mass analyser (Waters Corp., Manchester, UK) as described previously. Briefly, the mobile 
phase comprised 0.1 % formic acid in water (A) and 0.1 % formic acid in acetonitrile (B) 

















finally 95 % for 1 min, returning to 4 % B for 1.3 min prior to the next injection (at a flow 
rate of 0.6 mL/min at 45 °C).  The weak and the strong washes were 95:5 H2O/CH3CN (v/v) 
and 100% isopropanol respectively. 
The mass spectrometer was operated with electrospray ionisation (ESI) in positive ion mode 
in both full scan MS and MS/MS with nitrogen as the desolvation gas and argon as collision 
gas.  The source conditions were: capillary voltage, 1.0 kV; source offset, 50 V; desolvation 
temperature, 600 °C; source temperature, 150 °C, desolvation gas flow, 1000 L/hr; cone gas 
flow, 150 L/hr; nebuliser gas, 7.0 bar; collision gas, 0.15 L/hr.  Compound specific 
parameters, including cone voltage, ion transitions and collision energy, are as described 
previously [19] and detailed in Table S1 of the Supporting Information. 
2.5 Validation 
Method validation for the quantification of these amino compounds in rat in urine was 
followed the FDA guidelines for bioanalytical method validation [27] with linearity, dynamic 
range, limits of detection (LOD), accuracy, precision, specificity, matrix interferences, 
repeatability, stability and robustness investigated.  
2.5.1 Intra- and Inter-Assay Accuracy and Precision 
For the assessment of assay accuracy and precision a set of calibration standards prepared 
from stock A and six-fold replicates from stock B at the same concentration as six of the 
calibration standards were analysed, along with the appropriate QC samples. Intra- and inter-
assay accuracy was determined as the trueness of each measurement reported as a 
percentage was calculated using the formula.  
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐸𝑟𝑟𝑜𝑟 (𝐵𝑖𝑎𝑠) =



















The Relative Error (RE) for both within-(intra) and overall-(inter) batches must be 
within  15% at all QC levels, except for the LLOQQC where  20% is acceptable. 
The intra-day precision of the assay was estimated from the relative standard deviation 
(RSD) for the analysis of QC samples (6 replicates) with inter-day precision determined 
by analysis of the QC samples (6 replicates at 3 concentrations n= 18) on three 
consecutive days. To be acceptable intra- and inter- batch precision (CV) which must be 
≤15% for all QC levels, except for the LLOQQC where precision must be less than or 
equal to 20%. 
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (% 𝐶𝑉) =
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑉𝑎𝑙𝑢𝑒𝑠
𝑀𝑒𝑎𝑛 𝑜𝑓 𝑉𝑎𝑙𝑢𝑒𝑠
× 100 
Urine samples were included in the sample set in order to make it representative of a standard 
analytical batch. For acceptance at least four out of the six QC samples, and at least one at 
each of the three levels, in each batch, were required to give values within  15 % of their 
nominal concentrations. 
2.5.2 Specificity 
Samples of rat urine taken from six different animals were tested to determine whether 
endogenous components would interfere with the analysis. The stable isotope labelled 
analogues were used to assess gross matrix interferences. 
2.5.3 Autosampler Stability  
The autosampler stability (maintained at 4 °C) of the derivatised analytes was evaluated over 
the time course of the analysis. QC samples at 3 concentrations were analysed immediately 

















calibration curve and the concentrations obtained were compared with the nominal 
concentrations.  
2.6 Data Analysis 
The raw data were processed by the TargetLynx application package within MassLynx V4.1 
software (Waters Corporation, Milford, MA, USA). The raw data was mean smoothed and 
peak integration was performed using ApexTrak algorithm.  Further statistical analysis was 
performed on the resulting calculated concentrations using GraphPad Prism v5 (GraphPad 
Inc., UK).   
3 Results and Discussion 
3.1 Method Development 
Rodent urine is often high in protein and therefore the samples were mixed with cold 
methanol containing 0.1 % formic acid (v/v) and then centrifuged in order to remove the 
precipitate, as described in the experimental section, in order to preserve the integrity of the 
UHPLC columns. Acetonitrile, which often employed for protein precipitation in the case of 
plasma/serum proteins, proved to be unsuitable for the removal of urinary protein as its use 
resulted, in some cases, in phase separation (presumably due to high salt content in the 
affected samples). The derivatization procedure and chromatographic separation employed 
were the same as those previously described for human plasma/serum [19]. As described, this 
combination provided the basis for rapid sample analysis whilst nevertheless preserving the 
resolution of isomeric/isobaric analytes including β-alanine and alanine; γ-amino-n-butyric 
acid (Gaba), β-aminoisobutyric acid (BAIBA), α-amino-n-butyric acid, sarcosine; 1-
methylhistidine and 3-methylhistidine: isoleucine and leucine (Figure 1). In developing this 

















thiol-containing amino acids cysteine and homocysteine.  Both of these analytes are well 
known to be unstable, rapidly forming disulphides such as cystine and homocystine. As no 
provision is made for stabilizing these compounds during the collection of urine samples 
from rodents housed in metabolism cages, as performed in this study, the determination of the 
oxidised forms of these analytes represents a pragmatic solution to determining total urinary 
excretion of these analytes. Should accurate determination of the free thiols also be a 
requirement a more bespoke assay (e.g. see [28]) would be recommended. As illustrated by 
the data provided in Table 1, the separation demonstrated excellent repeatability based on the 
values obtained for the standard deviation (STDEV) and coefficient of variance (% CV) of 
the retention times of the standards calculated from the ULOQQC samples over the three 
days of validation (n = 18).  
3.2 Validation 
Although method validation for biomarkers has been discussed, there is still limited guidance 
for the validation of exploratory biomarkers, where the rigor of validation necessary differs 
from highly regulated clinical and drug monitoring environments requiring FDA validation.  
Therefore, a fit-for-purpose approach to validation has been applied here, as far as possible 
according to the FDA Guidance for Bioanalytical Method validation [27].  Assay validation 
was performed on three occasions, on three separate days, over the concentration range of 
0.2-200 µM for all of the analytes.  Since the sample preparation for rat urine samples 
involved a 1:3 (v/v) dilution step for protein precipitation, the actual measured concentration 
range in urine is 0.8-800 µM.  The assay was found to be valid over the concentration range 
0.6-200 µM (biological range 2.4-800 µM) for 14 of the 20 amino acids initially considered 
for absolute quantification using isotopically labelled IS. The LLOQ was raised to 6 µM 
(biological LLOQ 24 µM) for alanine, arginine, glycine, serine, tryptophan and valine.  Of 

















which passed the validation criteria for concentrations as low as 0.2 µM but, pragmatically, 
the LLOQ was set to 0.6 µM for all analytes with the exception of alanine, arginine, glycine, 
serine, tryptophan and valine where the LLOQ was 6 µM.   
The additional 18 amino compounds monitored here for relative quantification were included 
in the validation study to examine their potential for absolute quantification using substitute 
internal standards.  Of these, nine passed the validation criteria, with 1-methylhistidine, 3-
methylhistidine, 4-hydroxyproline, ethanolamine, sarcosine, and β-aminoisobutyric acid (2-
amino-isobutyric acid) capable of achieving LLOQ’s of 0.6 µM.  For carnosine, citrulline and 
cystathionine LLOQ’s of 6 µM were used as they were not quantifiable with a LLOQ of 0.6 
µM.  From the data presented here, these compounds would seem to be quantifiable using the 
current assay, with the caveat that, in the absence of an authentic isotopically labelled IS, 
such analyses may be less well controlled than for the other analytes.  The remaining nine 
amine metabolites (taurine, homoserine, β-alanine, γ-amino-n-butyric acid (4-aminobutanoic 
acid, GABA), hydroxylysine, aminoadipic acid, ornithine, homocystine and α-amino-n-
butyric acid (2-aminobutanoic acid)) were excluded from the quantitative validation while 
approximate, semi-quantitative, concentrations or fold changes can be calculated. 
The intra-day and inter-day validation results for the QC standards across the three days of 
validation are summarized in Table S2 of the Supporting Information.  The coefficient of 
variation for intra-day precision ranged from 0.89 to 20.1 % with the intra-day accuracy 
ranging from 0.03 to 20.7 %.  The inter-day coefficient of variance for each QC standard for 
the 29 amino acids ranged from 2.35 to 15.7 % and the corresponding inter-day mean bias 
ranged from 0.02 to 14.0 %.  The precision of the inter-day back calculated standards across 
the three days of validation ranged from 0.24 to 20.2 %, with the corresponding mean bias 

















3.2.1 Matrix Effects 
The method was found to be selective for the analytes of interest with no interferences found 
at the retention times of any of the compounds or stable isotope labelled analogues 
investigated. Stable isotope labelled (SIL) compounds were used to assess gross matrix 
effects, where SIL standards were spiked into calibration solvent at 1 µg/mL to provide 
reference solutions (n = 6) and compared with those of standards spiked into prepared matrix 
samples at the same final concentration.  Six independent sources of matrix (rat urine) were 
investigated.  Urine matrix samples from each source were protein precipitated, centrifuged, 
then spiked with SIL compounds and derivatised.  The matrix factors measured across the six 
sources of matrix were shown to be less than 20 % for all analytes (Supporting Information 
Table S3). 
3.2.2 Autosampler Stability 
Autosampler stability showed no decline in response noted over the time course of the 
analysis.  Over the period of a 7 hr run, the low, medium and high QC samples were 
quantified at regular time intervals.  A summary of the data acquired is provided in Table S4, 
illustrating that there was no significant reduction in the observed values for the low, medium 
and high QC samples.  
3.3 Analysis of Control Rat Urine 
The assay was then applied to the analysis of total 24-hour control rat urine samples collected 
over a period of 7 days. The amino acids detected, and the concentrations determined for 
them, are shown in Table 2.  Of the 29 amino acids validated here for absolute quantification, 
27 were quantifiable in the 24 hr rat urine samples analysed, with carnosine and cystathionine 
below their respective LLOQs. Concentrations (n = 10) of the amino compounds that were 

















detected but quantification was not attempted in the absence of suitable of stable isotope 
labelled internal standards.  Box plots for each of the quantified amino acids are shown in 
Figure 2, illustrating the spread of urinary concentrations taken from the 10 animals every 24 
hours and the corresponding fluctuations observed in samples over the 7 day collection 
period. There are few reports detailing baseline concentrations for all amino acids in rodent 
biofluids. However, a similar study recently described amino acid concentrations in rat and 
mouse biofluids and tissues, and while the calculated concentrations in the present analysis 
agree for certain analytes, there are some large difference between others [29]. The 
concentrations of biomarkers are known to be subject to large perturbations resulting from 
the type and time of urine sampling, urine concentration, and flow rate effects [30], as well as 
factors such as dietary components, highlighting the need for standardised collection and 
treatment for harmonized sample analyses.  Several normalisation strategies have been 
proposed and applied to such analyses of urine in an attempt to account for such differences 
[31].  Normalisation to urine creatinine is a frequently applied approach to control for 
variations in urine flow rate, assuming the urinary creatinine excretion is constant across and 
within individuals [32].  Here, two alternative commonly applied normalisation strategies for 
urine analysis, based on total urine volume and osmolarity, were also considered to correct 
for variation resulting from differences in urine concentration. These comparisons with non-
normalised urine concentrations are illustrated in Figure 3 for the difference in urinary 
alanine concentrations. Although there are some minor changes noted in the amino acid 
measurements depending on the normalisation approach employed, there were no significant 
changes to the overall trends in the data.  This observation was repeated for all of the amino 
acids measured (data provided in Supporting Information Tables S5 and S6 for normalisation 
to total 24h-urine volume and osmolarity respectively).  An example urine amino acid profile 



















A RP-UPLC-MS/MS method, employing derivatisation with the AccQTag Ultra
TM
 reagent, 
with a total run time of 7.5 min, was developed and validated for the targeted analysis of 
amino acids and biogenic amines in rat urine.  The method provides the resolution of a 
number of isomeric and isobaric metabolites and, via the use of stable isotope labelled 
internal standards, provides a specific, accurate, reproducible and, sensitive method for 29 
amino compounds detected in rat urine. A further nine compounds can be monitored to 
generate relative, fold change information. The assay requires only 20 µL of sample but 
enables quantification in the range of 1.2-12 fmol on column.  The results obtained when the 
method was applied to the measurement of amino acid concentrations in urine from healthy 
male Sprague-Dawley rats demonstrate the potential of this approach for the targeted analysis 
of amino compounds in rodent urine. 
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Figure 1. Typical chromatogram of the 38 amino acid standard mix at 200 µM (400 fmol on column) including 
separation of the isomeric and isobaric species.  
Figure 2. Box plots for each of the quantified amino compounds present in control rat urine samples taken every 
24 hrs over a 7-day period. 
Figure 3. Box plots illustrating changes in average rat urinary alanine concentration (n=10) in total urine 
collected every 24 hrs without normalisation (a), with normalisation to 24h-urine volume (b) and with 
normalisation to osmolarity (c). 
Figure 4. Scaled amino acid profiles of a rat urine derived from the targeted LC-MS/MS amino compound 
analysis. Carnosine (analyte no. 6), cystathionine (analyte no. 26) and homocysteine (analyte no. 34) were not 




















Table 1. Amino acids detected in the separation shown in Figure 1.  Average retention times (min), standard 
deviation (STDEV) and coefficient of variance (% CV) are calculated from the ULOQQC samples over the 
three days of validation. 
Peak No. Amino Acid Average RT (min) STDEV* CV (%)* 
1 Histidine 1.51 0.01 0.42 
2 3-methylhistidine 1.68 0.01 0.44 
3 4-hydroxyproline 1.75 0.00 0.24 
4 1-methylhistidine 1.76 0.01 0.36 
5 Asparagine 1.96 0.00 0.25 
6 Carnosine 1.97 0.00 0.23 
7 Arginine 1.99 0.01 0.35 
8 Taurine 2.18 0.00 0.15 
9 Glutamine 2.26 0.01 0.22 
10 Serine 2.28 0.00 0.14 
11 Homoserine 2.42 0.00 0.18 
12 Ethanolamine 2.43 0.00 0.14 
13 Glycine 2.51 0.01 0.22 
14 Aspartic acid 2.65 0.00 0.18 
15 Citrulline 2.73 0.00 0.18 
16 Sarcosine 2.80 0.00 0.16 
17 Glutamic acid 2.87 0.00 0.17 
18 β-alanine 3.02 0.01 0.17 
19 Threonine 3.06 0.00 0.16 
20 Alanine 3.42 0.01 0.15 
21 γ-amino-n-butyric acid 3.47 0.01 0.14 
22 Aminoadipic acid 3.58 0.00 0.07 
23 Hydroxylysine 3.58 0.00 0.00 
24 Proline 3.74 0.00 0.10 
25 β-aminoisobutryic acid 3.75 0.00 0.09 
26 Cystathionine 3.83 0.01 0.13 
27 Ornithine 3.83 0.01 0.13 
28 Cystine  4.05 0.00 0.11 
29 α -amino-n-butyric acid 4.06 0.00 0.11 
30 Lysine  4.07 0.00 0.09 
31 Tyrosine 4.42 0.01 0.12 
32 Methionine 4.55 0.00 0.08 
33 Valine 4.60 0.00 0.11 
34 Homocystine 4.86 0.00 0.00 
35 Isoleucine 5.20 0.00 0.09 
36 Leucine 5.28 0.01 0.10 
37 Phenylalanine 5.42 0.00 0.04 



















Table 2. Amino acid concentrations (µM) determined in rat urine samples taken every 24 hrs for 7 days. 












Mean Concentration (µM) (n = 10) 
0 hr 24 hr 48 hr 72 hr 96 hr 120 hr 144 hr 168 hr 
1-methylhistidine 4 22.1 34.9 22.5 32.7 21.6 37.4 43.3 25 
3-methylhistidine 2 10.6 9.99 8.75 9.84 8.1 8.48 8.9 7.94 
4-hydroxyproline 3 64.1 76.2 65.4 59.8 46.3 55.9 66.9 57.1 
β-aminoisobutyric acid 25 11 10.6 8.92 10.7 8.8 10.79 10.9 9.58 
Alanine 20 217 202 179 206 183 189 188 150 
Arginine 7 84.5 75 66 94.4 76.4 92.1 88.2 74.7 
Asparagine 5 133 135 123 140 132 126 135 116 
Aspartic acid 14 20.4 21.7 20.6 29.7 34.8 35.7 30.6 24.7 
Citrulline 15 12.2 12.5 10.8 11.9 10.7 11.2 10.6 9.51 
Cystine  28 5.38 5.31 5.25 5.74 6.54 6.61 7.04 5.72 
Ethanolamine 12 531 512 483 486 438 435 483 447 
Glutamic acid 17 56.9 64.2 74.2 193 133 186 162 88.3 
Glutamine 9 233 219 202 136 206 151 164 196 
Glycine 13 89.7 94.1 90.7 107.9 89.8 98.2 99.4 83.2 
Histidine 1 61.6 64.9 52.9 66.6 50.8 64.3 61.8 52.6 
Isoleucine 35 33.6 28.6 27.8 39 33.7 34.3 36.5 28.5 
Leucine 36 30.2 31.1 28.7 32.6 33.1 30.9 32 27 
Lysine  30 115 119 109 133 131 133 129 110 
Methionine 32 22.7 23.2 21.1 25.7 27.7 22.9 23.5 20.8 
Phenylalanine 37 24.9 24.5 23 27.2 25.6 26 25.4 21.5 
Proline 24 67.3 73.1 63.7 77.3 67.1 81.2 78 55.7 
Sarcosine 16 93.4 90.7 78 77.5 58.5 51.9 54.9 56.5 
Serine 10 134 127 116 123 111 110 106 98.1 
Tryptophan 38 <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ 
Tyrosine 31 25.2 26.6 22 25.7 24.3 26.3 25.8 20.4 



















 A reversed-phase UPLC-MS/MS assay for amino acids and biogenic amines in rat 
urine has been developed for exploratory metabolic phenotyping.   
 The method uses derivatisation with 6-aminoquinolyl-n-hydroxysuccinimidyl 
carbamate for retention and sensitive MS detection. 
 Limits of detection were 1.2-12 fmol on column with 20 µL of sample..  
 38 Amino compounds were analysed in 7.5 minutes with baseline resolution of 
critical isomers.  
 Assay validation provided for quantification of 29 amino compounds and monitoring 
for a further 9 over the range 0.6-200 µM. 
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